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The role of tumor-associated macrophages in
tumor vascularization
Chunqing Guo1, Annicole Buranych1, Devanand Sarkar1,2,3, Paul B Fisher1,2,3 and Xiang-Yang Wang1,2,3*
Abstract
Tumor vascularization is a highly complex process that involves the interaction between tumors and their
surrounding stroma, as well as many distinct angiogenesis-regulating factors. Tumor associated macrophages
(TAMs) represent one of the most abundant cell components in the tumor environment and key contributors to
cancer-related inflammation. A large body of evidence supports the notion that TAMs play a critical role in
promoting the formation of an abnormal tumor vascular network and subsequent tumor progression and invasion.
Clinical and experimental evidence has shown that high levels of infiltrating TAMs are associated with poor patient
prognosis and tumor resistance to therapies. In addition to stimulating angiogenesis during tumor growth, TAMs
enhance tumor revascularization in response to cytotoxic therapy (e.g., radiotherapy), thereby causing cancer
relapse. In this review, we highlight the emerging data related to the phenotype and polarization of TAMs in the
tumor microenvironment, as well as the underlying mechanisms of macrophage function in the regulation of the
angiogenic switch and tumor vascularization. Additionally, we discuss the potential of targeting pro-angiogenic
TAMs, or reprograming TAMs toward a tumoricidal and angiostatic phenotype, to promote normalization of the
tumor vasculature to enhance the outcome of cancer therapies.
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Introduction
It is well known that progressive tumors require vascular
development for delivery of oxygen and nourishment into
the tumor to facilitate their survival, growth and capacity to
metastasize [1]. Tumor vascularization, or angiogenesis,
represents one of the hallmarks of cancer and plays an
essential role in tumor progression, invasion and metas-
tasis [2,3]. Blood vessels dramatically increase in most
tumors during the tumor transition to malignant states, a
process termed as the “angiogenic switch” [4,5]. Tumor
vascularization is influenced by many molecular and
cellular events in the tumor microenvironment (TME),
since transformed cells secrete pro-angiogenic molecules
that recruit and activate not only endothelial cells (ECs),
but also stromal cells such as macrophages. Unlike physio-
logical or developmental angiogenesis, tumor vasculatures
are known to be structurally and functionally abnormal,
characterized by poor blood flow, leakiness and dilation
[4,5].
Macrophages are of the myeloid cell lineage and consti-
tute the first line of innate defense against invading
pathogens by engulfing microbes or presenting antigens to
T cells [6]. They also play crucial roles in tissue homeosta-
sis, repair, and remodeling via production of various
cytokines, chemokines, growth factors and proteolytic
enzymes [6-8]. An enhanced number of inflammatory
leukocytes are often found in mouse and human tumors
compared with surrounding normal tissues [9,10], suggest-
ing a potential link between these cells and tumor
vascularization. More specifically, the most abundant cell
population among the inflammatory cells in the solid
tumor environment, tumor associated macrophages
(TAMs), have garnered considerable interest in recent
years as key initiators of chronic inflammation in the TME
by producing growth factors and inflammatory cytokines
[11]. Accumulating evidence suggests that TAMs act as a
key effectors, provoking a pro-angiogenic outcome during
the “angiogenic switch” [12,13], and play a prominent role
in stimulating tumor angiogenesis and progression [12,14].
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Macrophage polarization in the tumor
environment
The highly malleable macrophages mainly originate
from blood monocytes infiltrating peripheral tissues
and subsequently acquire distinct characteristics as a
result of environmental cues [6]. TAMs are reportedly
present in both perivascular and hypoxic regions of
different mouse and human tumors [15-17]. The TME
often directs macrophage polarization from the M1
(classically activated) state, which is associated with an
anti-angiogenic and anti-tumorigenic response, to the
M2 (alternatively activated) state, a phenotype that
promotes angiogenesis and tissue remodeling as well
as immunosuppression [5,18,19]. TAMs phenotypically
resemble M2-like macrophages due to their ability
to secrete pro-angiogenic factors promoting tumor
vascularization and induce development of abnormal
vessels [20,21]. Murine TAMs display signature mole-
cules of M2-like or alternatively activated macrophages,
such as arginase-I, scavenger and mannose receptors,
vascular endothelial growth factor (VEGF), matrix metal-
loproteinases (MMPs), osteopontin and transforming
growth factor-β (TGF-β) [22-24]. In contrast, TAMs
often display variable phenotypes depending on the stage
of tumor development. For example, while TAMs are
biased toward the M2-like state in advanced tumors, in
early stages or in regressing tumors, TAMs tend to
resemble the M1-like phenotype, further supporting
angiogenesis inhibition and anti-tumor immunity by
these pleiotropic cells [5,25].
Molecular profiling demonstrates that TAM subpopu-
lations express both canonical M1 and M2 markers, al-
though at significantly different levels [16,17,26].
Distinct subpopulations with a variably skewed M2-like
phenotype coexist in mouse and human tumors
[16,17,27]. Thus, it is conceivable that the dynamic
changes in TAM phenotypes within the TME regulate
the tumor vascular network, including angiogenesis and
abnormal vessel development. The predictive value of
M2-macrophage-associated markers (e.g., CD163) dem-
onstrated in clinical studies also supports the notion that
TAM polarization is of disease relevance [28]. Similar re-
sults obtained in mouse and clinical studies demonstrate
that high macrophage frequency in many human cancer
types closely correlates with increased tumor angiogen-
esis, metastasis, and poor prognosis [28-31].
While the correlation between TAMs and cancer
prognosis or angiogenesis has been well described in
different forms of human cancer [32], our understanding
of the direct correlation between TAMs with an M2-like
phenotype or characteristics and vascularization in
human cancer is relatively limited. A few studies
documented that the levels of CD163- or heme oxygenase-
1-expressing macrophages are associated with the numbers
of vessels in human intrahepatic cholangiocarcinoma [33]
or glioma [34].
It was recently shown that both the origin and phenotype
of TAMs might differ in primary tumors and metastases
[35]. Such complexity emphasizes the diversity of TAM
programming that is directed by the surrounding milieu
within individual tumors [5,19,36,37]. Their dynamic inter-
action with the TME constantly shapes TAM phenotype
and functioning, favoring tumor vascularization, invasion
and subsequent metastasis. Therefore, M1/M2 classifica-
tion of macrophages provides a useful working scheme;
however, it is an oversimplification of the complexity of the
functional states of macrophage activation as well as the
heterogeneity and plasticity of macrophage in the TME.
The polarization of TAMs to a pro-angiogenic pheno-
type is regulated by multiple factors in the TME. For
example, signals derived from stromal and inflammatory
cells, hypoxia, genetic or epigenetic changes of cancer cells
[20], as well as several molecular signaling pathways,
including NF-κB [23,38], Notch [39] and Wnt5a [40], are
important regulators of polarization of TAMs. Further-
more, transcription factors, such as signal transducer
and activator of transcription 6 (STAT6), peroxisome
proliferator-activated receptor-gamma (PPAR-γ), and
c-Myc, are also involved in alternative activation of
TAMs [41,42]. A recent study reported that macrophage-
derived migration inhibitory factor (MIF) is an important
determinant of the alternative activation of TAMs in
melanoma-bearing mice [43]. MIF deficiency or treat-
ment with a MIF antagonist attenuates tumor-induced
TAM polarization and reduces the expression of pro-
angiogenic genes in TAMs [43].
Regulation of tumor vascularization by TAMs
Mononuclear phagocytic lineage cells, such as TAMs,
are recognized as major contributors in the angiogenic
process [5,44]. The potential role of macrophages in
regulating tumor angiogenesis was initially proposed in
the early 1990s [45]. The positive correlation between
microvessel density and the level of infiltrating TAMs in
tumor vessel areas, as well as poor prognosis in cancer
patients, further supports the pro-angiogenic functions
of these cells during human cancer progression
[19,31,46]. Regulation of tumor vascularization by TAMs
has been extensively investigated in animal tumor
models [47-49].
When a mouse strain that develops oncogene-induced
mammary tumors (MMTV-PyMT, mammary tumor
virus promoter-driven polyoma middle T oncogene) was
crossbred with mice carrying a homozygously mutated
colony stimulating factor-1 (CSF-1) gene, the resulting
ablation of macrophages delayed the angiogenic switch
and tumor progression, whereas restoration of macro-
phage infiltration rescued the vessel phenotype [48].
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Conversely, overexpression of the CSF-1 transgene in
the mammary epithelium was found to promote the
recruitment of monocyte/macrophages, which correlated
with accelerated tumor progression in MMTV-PyMT
mice in comparison to the nontransgenic counterparts
[47]. Indeed, macrophages have a direct effect on the
angiogenic switch (i.e., transition from a quiescent to a
growing vasculature) and formation of the vessel net-
work, subsequently accelerating the tumors’ progression
to malignancy [1,48].
Extensive studies have established the roles of TAMs
in promoting tumor angiogenesis or vascularization
through their immense production of pro-angiogenic
growth factors and cytokines. Transcriptional profiling
analysis of late-stage mammary tumors from MMTV-
PyMT mice documented that TAMs are highly enriched
in transcripts encoding angiogenic factors, such as well-
characterized VEGF, in comparison to a similar cell
population from the spleens of non-tumor-bearing mice
[50]. In tumor hypoxic areas, TAMs represent a critical
source of VEGF-A, which functions as a potent mitogen
for ECs by binding to VEGFR1/2 in human breast
tumors [51]. Genetic studies indicated that VEGF-A
produced by TAMs encompasses one of the essential
factors involved in regulating the onset of the angiogenic
switch and progression of MMTV-PyMT mammary
mouse tumors [48,52,53]. Stockmann et al. recently
showed that targeted ablation of the vegfa gene in
myeloid cells attenuated the formation of what is typic-
ally a high-density vessel network, thus blocking the
angiogenic switch in solid tumors [54]. However, the loss
of VEGFA in tumor-infiltrating myeloid cells (the majority
of which are TAMs) failed to inhibit the progression of
subcutaneous and autochthonous (MMTV-PyMT) tumors,
although it increased the susceptibility of tumors to chemo-
therapeutic cytotoxicity [54]. A recent study reported that
depletion of TAMs reduced total vegf mRNA levels but did
not affect vascular density in MMTV-PyMT tumors [55].
These studies suggest that VEGF-derived from other cell
types in the TME, such as cancer cells [56], also contributes
to tumor angiogenesis and progression. In addition,
TAMs have the ability to produce a number of other
pro-angiogenic factors, including growth factors and
inflammatory cytokines or mediators, e.g., basic fibroblast
growth factor (bFGF), macrophage-inhibitory factor,
platelet activating factor, prostaglandin E2, osteopontin,
adrenomedullin, PlGF, PDGF, TGF-β, IL-1β, IL-8 and
TNF-α [57-61].
Tumor and inflammatory cells of the TME are sur-
rounded by an extracellular matrix (ECM). TAMs affect the
composition of the ECM by producing various matrix-
remodeling proteolytic enzymes, such as MMP-2, MMP-7,
MMP-9, MMP-12 [19,62]. TAMs also serve as the primary
source for cathepsin protease activity in pancreatic cancer
and mammary tumors; removal of TAM-derived cathep-
sin B or cathepsin S in these tumors impairs tumor angio-
genesis [63,64]. The MMPs can induce degradation of the
sustaining basement membrane and remodeling of ECM
[65], thus promoting the migration and proliferation of
ECs. MMP-9 also mobilizes the latent forms of VEGF
sequestered in the ECM and enhances their bioavailability
in RIP1-Tag2 mice, a pancreatic islet carcinogenesis model
[66]. Indeed, MMP-9 produced by tumor infiltrating
myeloid cells, including TAMs, or bone marrow (BM)
cells is crucial for tumor angiogenesis and progression
[66,67]. A subsequent study demonstrated that targeting
macrophages expressing MMP-9 suppresses angiogenesis
development in estrogen-treated K14-HPV16 transgenic
mice, a model of human cervical carcinogenesis [68]. Two
recent studies using mouse models of mammary carcin-
oma and glioblastoma (GBM) also support the essential
role of MMP-9 when associated with BM cells or macro-
phages in increasing VEGF bioavailability and initiating
tumor vascularization [69,70]. Thymidine phosphorylase,
a pro-angiogenic enzyme expressed in TAMs, has also
been associated with tumor vascularization and poor
prognosis in cancer patients [71-74].
Molecular pathways regulating the
pro-angiogenic TAMs
TAMs are mobilized from the BM and recruited to the
TME to promote tumor vascularization by tumor-
derived cytokines or chemokines. CSF-1, also known as
macrophage-colony stimulating factor (M-CSF), is the
main regulator of the proliferation, differentiation,
survival, and chemotaxis of monocytes/macrophages
in tumor-bearing mice [6,47,75]. Depletion or inhib-
ition of CSF-1 suppresses the infiltration of TAMs,
which is associated with a significantly impaired tumor
progression [47,75]. Recent studies demonstrated that
VEGF-A is a potent chemoattractant for macrophages
and that it can directly orchestrate the infiltration of
monocytes/macrophages into tumors by engaging
VEGFR1 signaling [76,77]. Monocyte chemoattractant
protein-1 or (C-C motif ) ligand 2 (MCP-1/CCL2) is a
chemokine involved in recruiting monocytes to
inflamed tissues [78]. MCP-1/CCL2 expression in
human tumors correlates with monocyte/macrophage
infiltration, as well as advanced tumor stages and
metastatic relapse in breast cancer patients [79,80].
MCP-1/CCL2 can also stimulate macrophages to
secrete urokinase-type plasminogen activator (uPAR)
and MMP-9, both of which have the ability to remodel
the tumor ECM [66,81]. In prostate cancer, recruiting
pro-angiogenic macrophages into primary and meta-
static tumors is one of the mechanisms by which
MCP-1/CCL2 promotes tumorigenesis and metastasis [82].
Moreover, MCP-1/CCL2 and IL-6 induce an amplification
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loop that promotes TME-induced macrophage polarization
toward the M2-like phenotype via the inhibition of
caspase-8 cleavage and enhanced autophagy [83]. It is also
worth noting that TAMs themselves are a rich source of
various inflammatory chemokines. Thus, chemokines abun-
dantly produced by TAMs also amplify the recruitment of
myeloid cells, further extending the aberrant vascularization
within the TME [11,84].
The chemokine (C-X-C motif ) ligand 12 (i.e., CXCL12),
also known as stromal cell-derived factor-1 (SDF-1), is
expressed by tumor cells, fibroblasts and ECs within the
tumors. Similar to VEGF, CXCL12 is highly upregulated
in hypoxic tumors and provides a strong chemotactic
signal for cells expressing CXCR4 or CXCR7, such as
myeloid-lineage cells and ECs [70,85-88]. Interestingly,
CD163+ perivascular macrophages in human metastatic
melanoma express high levels of CXCL12 and autocrine
CXCL12 production modulates the differentiation of
monocytes toward a distinct program with pro-angiogenic
functions, indicated by upregulation of VEGF and the
angiogenic chemokine, CCL1 [89].
Placental growth factor (PlGF), a member of the
VEGF family, can bind VEGFR1 and neuropilins
expressed on ECs, macrophages and tumor cells [90].
The pro-angiogenic activity of PlGF in tumors is
partially mediated by its ability to recruit VEGFR1+ mono-
cytes/macrophages into tumors [58]. Blocking stromal- or
tumor-produced PlGF inhibits tumor vascularization and
TAM accumulation [58,91]. Deficiency of stromal PlGF
alters the pro-angiogenic phenotype of TAMs and causes
reduced tumor blood vessels [92].
The ability of TAMs to produce angiogenic factors is
regulated by several transcription factors and signaling
pathways. Activation of signal transducer and activator of
transcription 3 (STAT3) mediates the function of TAMs
in angiogenesis by upregulating several pro-angiogenic
factors, e.g., VEGF and bFGF [93]. Tumor cell-derived
soluble factors and direct cell-cell contact with tumors
cells induce strong STAT3 activation in macrophages
[93,94]. STAT3-regulated factors produced by both
tumor cells and tumor-associated myeloid cells or TAMs
also induced constitutive activation of STAT3 in tumor
ECs, underscoring a central role of STAT3 signaling in
mediating multidirectional crosstalk among tumor cells,
myeloid cells and ECs in the TME that contributes to
tumor angiogenesis [95].
The transcription factor Ets2 serves as a target for
CSF-1 signaling pathways that regulate macrophage
functions during inflammation [96,97]. Conditional
ablation of Ets2 in TAMs results in decreased angiogenesis
and reduced growth of mouse mammary tumors, as well
as the reduced frequency and size of lung metastases, sug-
gesting that Ets2 serves as the driver for a transcriptional
program that promotes angiogenesis of breast tumors [98].
The Ets2 mechanism of action in TAMs is suggested to
involve direct repression of anti-angiogenesis genes (Thbs1,
Thbs2, Timp1, and Timp3) [98]. The NF-κB [99], TSC2–
mTOR [100] and FLT-1 [101] signaling pathways also play
important regulatory roles in the pro-angiogenic functions
of TAMs.
Hypoxia is a common feature of solid tumors and a
major driver of angiogenesis [102]. Many TAMs accumu-
late in hypoxic and/or necrotic areas of tumors, probably
due to the release of hypoxia-induced chemoattractants
such as VEGF and endothelins [81]. Upregulation of
hypoxia-inducible factor-1α (HIF-1α) in the highly
hypoxic GBMs results in the elevation of both VEGF and
CXCL12, promoting the influx of BM-derived myeloid
cells such as MMP-9-producing TAMs in the TME
[70]. The knockdown of prolyl hyroxylase 2 (Phd2), a
molecular oxygen sensor and negative regulator of HIF-
1α, in human colon cancer increases the number of
CD11b+ tumor-associated myeloid cells and promotes
angiogenesis [103]. These findings highlight the import-
ant role of tumor hypoxia for the recruitment of
pro-angiogenic myeloid cells, including TAMs. Once
TAMs are recruited to the hypoxic areas, TAMs respond
to hypoxia by upregulating hypoxia-inducible transcrip-
tion factors (e.g., HIF-1α) for metabolic adaption, lead-
ing to an increase in transcription of a number of genes
(e.g., VEGF, CXCL8) involved in regulating tumor
vascularization [51,70,104]. In addition, TAMs also
promote angiogenesis in the hypoxic condition by
suppressing the expression of angiogenesis inhibitors,
e.g., vasohibin-2 [105].
Several findings support a causal relationship between
STAT3 activation and HIF-1α-dependent angiogenesis.
STAT3 has been shown to be an important regulator of
HIF-1α expression under both hypoxia and growth signal-
ing conditions [106-108]. Activated STAT3 increases HIF-
1α protein levels by blocking degradation or enhancing its
de novo synthesis, which in turn enhances VEGF expres-
sion [109]. A novel autocrine loop (IL-6/STAT3/HIF-1α)
that operates in cancer cells was recently discovered
[110,111]. Interestingly, elevated STAT3 activity can in-
crease HIF-1α promoter activity in both cancer cells and
nontransformed, tumor-associated myeloid cells in the
TME [107].
TAM-related myeloid cells in tumor
vascularization
Studies in mice have shown that tumors can recruit large
numbers of monocytes, commonly regarded as the
prospective TAM precursors, by secreting chemokines
[12,112]. Upon differentiation into TAMs, these cells
promote tumor growth, invasion, and metastasis by
supporting the proliferation, survival, and motility of
transformed cells, as well as tumor vascularization and
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suppression of antitumor immunity [35,36]. Although it
has been reported that monocytes proliferate within
tumors to generate TAMs [16], it is still unclear whether
Ly6C+ “inflammatory monocytes” or Ly6C– “resident
monocytes” [113] are the primary source of TAMs in mice
[16,114]. Therefore, TAMs originate from myeloid pro-
genitors in response to tumor-secreted soluble factors,
although the origin of TAMs in human cancer remains
unclear.
A subpopulation of myeloid cells characterized by
their expression of the angiopoietin receptor Tie2, also
known as Tie2 expressing monocytes/macrophages
(TEMs), has been identified in both human and murine
tumors [115-117]. TEMs preferentially localize in the
vicinity of tumor blood vessels [115-117]. Co-injection
of tumor cells and TEMs derived from mouse mammary
tumors into mice enhances tumor vascularization com-
pared to their Tie2− counterparts, while elimination of
these cells using a suicide gene strategy significantly
impairs tumor angiogenesis in subcutaneous mammary
tumors or orthotopic human gliomas [115]. Similarly,
human TEMs also provoke marked vascularization of
human gliomas grown subcutaneously in nude mice
[116], suggesting a fundamental role of TEMs in regulat-
ing angiogenesis. In addition, it has recently been sug-
gested to use TEM frequency as a diagnostic marker for
angiogenesis in hepatocellular carcinoma, potentially
reflecting angiogenesis in the liver [118]. Gene expres-
sion profiling analyses show that tumor-derived TEMs
are a subset of TAMs expressing a distinct gene signa-
ture consistent with enhanced pro-angiogenic/tissue-re-
modeling activity and lower pro-inflammatory activity
[17]. Nonetheless, TEMs display an M2-like macrophage
polarization, indicated by the enhanced expression of
several scavenger receptors, including hemoglobin/hapto-
globin scavenger receptor (Cd163), scavenger receptor A
(SRA or CD204), mannose receptor (MRC1 or CD206),
hyaluronan receptor-1 (Lyve1), the lower expression of
pro-inflammatory factors, e.g., interleukin 1β (Il1b) and
nitric oxide synthase-2 (Nos2), and anti-angiogenic
mediators, e.g., interleukin 12 (Il12) and Cxcl10
[17,37].
Angiopoietins (ANGs) interactions with their receptor
Tie2 are shown to be an emerging regulator of leukocyte
trafficking and function in tumors [119]. Overexpression
of ANG2 in the tumor vasculature induces the direct
chemo-attraction of TEMs, indicated by enhanced recruit-
ment of TEMs and consequently increased microvessel
density in tumors [120]. ANG-2 markedly enhanced the
pro-angiogenic activity of TEMs and increased their
expression of two pro-angiogenic enzymes: thymidine
phosphorylase and cathepsin B [105]. Additional studies
using the approaches of ANG2 blockade or Tie2 knock-
down in MMTV-PyMT mammary carcinomas and RIP1-
Tag2 pancreatic insulinomas suggest that the surface
levels of Tie2 in TEMs or ANG2-Tie2 signaling is re-
quired for TEM interactions with adjacent tumor blood
vessels and subsequent tumor vascularization [15].
Tumors also recruit and expand myeloid-derived sup-
pressor cells (MDSCs), a heterogeneous population of
immature myeloid cells that are commonly identified by
their expression of Gr-1 (Ly6C/G) and immunosuppres-
sive activity [121,122]. Co-injection of MDSCs from
murine tumors significantly increases the growth rate and
blood vessel density of subcutaneous MC26 colorectal
tumors [123]. Both MDSCs and TAMs have a phenotype
similar to that of alternatively activated macrophages in the
mouse [124]. STAT3 is suggested to contribute to the
pro-angiogenic phenotype of TAMs and MDSCs [93].
Several lines of evidence suggest that MDSCs can mature
into TAMs [125,126]. Interestingly, the crosstalk between
MDSCs and TAMs results in increased production of
MDSC-derived IL-10 and decreased production of IL-12
by TAMs, which further promotes tumor progression
[127]. A recent study showed that hypoxia alters the func-
tion of MDSCs in the TME via HIF-1α and redirects their
differentiation toward TAMs [128]. In addition to tumor
cells, vascular ECs in the perivascular microenvironment
can produce CSF1 and promote the functional polarization
of M2-like macrophages that accelerate angiogenesis and
tumor growth [129].
TAMs, tumor vasculature and therapeutic
response
Although tumor angiogenesis provides a promising target
for the potential treatment of cancer, studies in mice and
cancer patients have shown that anti-angiogenic therap-
ies interfering with the VEGF pathway rarely induce
long-lasting tumor responses [130], possibly due to the
activation of VEGF-independent tumor vascularization
[131]. Tumor hypoxia induced by anti-angiogenic treat-
ment may promote the recruitment of BM-derived
myeloid cells, including TEMs, to the tumors through
chemotactic factors [131-133]. Therefore, the enhanced
mobilization of myeloid cells, or TAMs, and their subse-
quent recruitment to the tumors are likely to contribute
to the compensatory or alternative pro-angiogenic
programs that render a tumor refractory to the anti-
angiogenic blockade by VEGF antibodies [133]. Sorafenib,
a small molecule inhibitor of tyrosine protein kinases, e.g.,
VEGF receptor 2 (VEGFR2), platelet derived growth
factor receptor (PDGFR), and Raf kinases, also promotes
TAM infiltration and elevation of CSF-1, SDF-1α/
CXCL12 and VEGF in the tumors of hepatocellular
carcinoma xenografts [49]. Elimination of TAMs with
clodrolip (clodronate-containing liposomes) or Zoledronic
acid strongly enhances sorafenib inhibited tumor pro-
gression and angiogenesis compared to mice treated with
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sorafenib alone [49]. Additionally, TAM depletion or
CSF1R inhibitor synergizes with the anti-angiogenic ef-
fects of VEGF/VEGFR2 antibodies in controlling sub-
cutaneous human cancer xenografts [134,135].
The ability of myeloid cells, including TAMs, to notice-
ably limit the efficacy of anti-angiogenic therapies was
recently observed in mice treated with vascular-disrupting
agents (VDAs) that selectively cause the transient collapse
of tumor vasculature in order to achieve tumor destruc-
tion. However, concomitant tumor hypoxia and necrosis
are accompanied with increased CXCL12 production and
TEM infiltration in mouse mammary tumor models [86].
Blocking the recruitment of TEM using a CXCR4 antag-
onist or genetic ablation of TEM in tumor-bearing mice
significantly enhances the efficacy of a VDA, i.e., combre-
tastatin A4 phosphate [86].
TAMs and related myeloid cells are also associated with
the failure of other cancer therapies. Several lines of
evidence show that certain chemotherapeutic drugs en-
hance tumor recruitment of myeloid cells, e.g., TAMs,
therefore limiting therapeutic outcomes. In a chemoresis-
tant MCF-7 breast cancer model, combined chemotherapy
(cyclophosphamide, methotrexate, and 5-fluorouracil),
when used in conjunction with anti-CSF-1 antibodies,
displayed markedly enhanced antitumor efficacy [136]. The
CSF-1 blockade reduced TAM recruitment and angiogen-
esis, as well as down-regulated MMP-2 and MMP-12
expression in the tumor [136]. In the MMTV-PyMT
mammary tumor model, inhibiting TAM recruitment
using a selective CSF-1R inhibitor decreased blood vessel
density and enhanced the efficacy of paclitaxel, a first-
line treatment for metastatic breast cancer [55]. Add-
itionally, this study underscores the prognostic value of
the inverse correlation between the number of TAMs
and cytotoxic T cells in breast cancer patients [55].
Therefore, a high TAM concentration promotes the for-
mation of aberrant, hypo-perfused tumor vasculature
that limits the delivery of chemotherapeutic agents into
tumors. Furthermore, the ability of tumor-infiltrating
TAMs to promote tumor chemoresistance is, at least in
part, due to their suppression of the cytotoxic functions of
effector T cells. It was recently shown that Trabectedin, a
DNA-damaging agent approved for soft tissue sarcomas,
inhibited the growth of mouse fibrosarcomas mainly by
depleting monocytes and TAMs [137], suggesting that the
antitumor efficacy of certain cytotoxic agents may partially
rely on their ability to deplete pro-tumoral myeloid cells.
Radiotherapy (RT) is commonly used for treatment of
many human cancers. In addition to the tumor ECs [138],
emerging data underscores a possible role of tumor-
infiltrating leukocytes in the regulation of tumor
responses to RT [139]. Previous studies indicate a correl-
ation between high TAM numbers and poor tumor re-
sponses to irradiation in mouse tumors [140]. In a mouse
model of orthotopic human GBM, local RT and conse-
quent vascular destruction promotes the recruitment of
CD11b+ monocytes/macrophages via the up-regulation
of HIF1α [87]. These myeloid cells mainly expressed
F4/80 and Tie2 and were shown to promote tumor re-
vascularization and relapse [87]. Blocking CXCL12
inhibited the recruitment of these myeloid-cells in re-
sponse to RT and subsequently promoted the recovery
of tumor vasculature, as well as the regrowth of irradi-
ated tumors [87]. The same monocyte/macrophage cell
population was also shown to promote tumor recur-
rence post-RT in a model of human head and neck
squamous carcinoma in immune deficient mice [141].
It was also found that the use of anti-CD11b antibodies
dramatically reduced myeloid cell infiltration and en-
hanced tumor responses to RT [141]. A subsequent
study indicated that TEMs represent a major propor-
tion of the myeloid cells recruited and localized around
the tumor blood vessels after tumor irradiation [88]. It
is proposed that these cells play a key role in facilitating
tumor recurrence by promoting the survival of ECs and
subsequent tumor revascularization. Targeting TAM or
TAM-associated signaling to enhance the potency of
RT has been similarly demonstrated in several other
studies [142,143]. In addition to the rapid recruitment
of TAMs, the irradiated TME also favors the
polarization of M2-like macrophages that locate in
avascular, hypoxic areas [142]. Thus, the recruited
TAMs in irradiated TME are functionally similar to
those of M2-like macrophages driving tissue repair dur-
ing wound healing.
Reprogramming TAMs to normalize tumor
vasculature for improved anticancer therapy
There is an increasing amount of evidence supporting the
concept of targeting TAMs or blocking the pro-angiogenic
activity of TAMs to inhibit tumor vascularization and
improve the therapeutic index of conventional cancer
therapies [37,144]. Given the fact that macrophages of
certain phenotypes possess the intrinsic ability to destroy
cancer cells [5], reprograming pro-tumoral TAMs toward
an anti-tumoral phenotype may represent a strategy to
inhibit angiogenesis and provoke anti-tumor responses.
TNF-α is highly expressed by many human tumor types
and plays a critical role in the induction of the pro-
angiogenic phenotype of macrophages [145,146]. Eliminat-
ing leukocyte-derived TNF-α results in diffused vascular
hemorrhage, stromal necrosis, and reduced tumor growth
in MMTV-NeuT mice [147]. In addition, blocking TNF-α
skews tumor-associated MRC1+Tie2+ TAMs from a pro-
angiogenic phenotype to a pro-inflammatory/angiostatic
phenotype, indicated by the upregulation of IL-12. Specific
inhibition of the transcription factor NF-κB signaling in
TAMs stimulates them to convert into classically
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activated cytotoxic cells, characterized by elevated
IL-12 and MHC II expression [38]. The regression of
tumors caused by TAM phenotypic changes depends
on the tumoricidal activity of macrophages and natural
killer cells [38]. In addition, tumor-targeted delivery of
Th1 cytokine IFN-α using TEMs has been shown to
reprogram TAMs toward a pro-inflammatory pheno-
type, inducing vascular normalization and impairing
the growth of orthotopic gliomas and MMTV-PyMT
mammary carcinomas [148]. Reprograming of TAMs with
IFN-α also leads to a significant increase in CD11c+ macro-
phages or dendritic cells and provokes antitumor immune
responses [148].
B lymphocytes and secreted immunoglobulins G (IgGs)
were recently shown to promote skin carcinogenesis in
K14-HPV16 mice through their interactions with immuno-
globulin receptors (FcγR) expressed on tumor-infiltrating
myeloid cells [149]. The absence of FcγR shifts TAMs
from a pro-tumoral to an anti-tumoral phenotype, as
indicated by an upregulation of “M1-like phenotype”
genes (e.g., Il1b, Il1a, Nos2, Il12a, Cxcl10, Cxcl11) and a
downregulation of genes associated with macrophages with
“M2-like phenotype” or alternative activation (e.g., Cd163,
Il13, Il4, Ccl17). In mice that are prone to skin-tumors,
the lack of FcγR results in a reduced angiogenic re-
sponse, as well as a reduced incidence of squamous
cell carcinoma [149].
In addition to facilitating tumor angiogenesis, TAMs also
induce abnormal tumor vessels in the hypoxic TME [32],
thereby rendering tumors more resistant to cytotoxic ther-
apies [150-152]. Thus, TAM-targeted therapy, such as
TAM polarization, may potentially result in anti-angiogenic
vessel normalization that not only reduces the aggressive
phenotype of tumors, but also substantially enhances the
therapeutic potency of other cancer treatments [151,152].
TAM depletion increased chemotherapeutic efficacy has
been, at least partially, attributed to the normalization of
blood vessels and improved delivery of therapeutic drugs
[55,144].
Histidine-rich glycoprotein (HRG) is a heparin-binding
plasma protein with anti-angiogenic activities, and its
expression is downregulated in tumors. Intriguingly, HRG
is highly effective in inducing M1-like polarization of
TAMs by downregulating PIGF, as indicated by an
M2-like TAMs
(alternatively activated)
M1-like macrophages
(classically activated) 
Pro-angiogenic factors (e.g., 
VEGF), chemokines (e.g., 
CCL1), MMPs, IL-10, TGF- β, 
PGE2. 
CSF-1, MCP-1/CCL2, 
CXCL-12/SDF-1, PlGF, 
hypoxia 
TNF- blockade, 
IFN- , HRG
TAM reprogrammingTumor
HIF-1 , STAT3, Ets2
Notch, Wnt5a, TSC2-
mTOR, FLT-1
IL-12, CXCL10, IFN-β, 
NO
NOS2
Arginase-I
heme oxygenase-1
STAT1, IRF5 
Figure 1 Targeting TAMs to disrupt or normalize tumor vasculature. Tumor cell-derived factors (MCP-1, SDF-1), multiple signaling pathways
(Notch, Wnt5a, TSC2-mTOR and FLT-1) and transcription factors (HIF-1α, STAT3, Ets2) in the tumor environment recruit and/or polarize TAMs to an
M2 (alternatively activated) state. TAMs produce pro-angiogenic factors and MMPs to promote the tumor vascularization during tumor growth
and progression. TAMs and aberrant tumor vasculature also contribute to the failure of anticancer treatments, such as anti-angiogenesis therapy,
chemotherapy and radiation therapy. TAM-targeted therapies can be designed to block the recruitment or pro-angiogenic activity of TAMs. TAMs
can also be “re-educated” and reprogrammed to become antitumor effector cells with an M1-like phenotype, characterized by high expression of CD86,
MHC-II and NOS2, enhanced production of IL-12, CXCL10, IFN-β and NO. These classically activated macrophages display anti-angiogenic, tumoricidal
and immunostimulatory activities, facilitating the eradication of cancer cells. Targeting of TAMs may also potentially lead to the normalization of tumor
vasculature, which synergizes with antitumor efficacy of other cytotoxic treatments, such as chemotherapy. HIF-1α, hypoxia-inducible factor-1α; HRG,
Histidine-rich glycoprotein; IRF5, interferon regulatory factor 5; MCP-1, monocyte chemoattractant protein 1; MMP, matrix metalloproteinase; NO, nitric
oxide; NOS2, nitric oxide synthase 2; PGE2, prostaglandin E2; SDF-1, stromal cell-derived factor-1; SRA, scavenger receptor A; STAT, Signal transducer and
activator of transcription; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor.
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increased production of angiostatic cytokines (e.g., IFN-β,
CXCL10 and IL-12) and a concomitantly decreased
expression of pro-angiogenic cytokines (e.g., CCL22,
IL-1β and TNF-α) [92]. Skewing TAMs toward a pro-
inflammatory phenotype by HRG treatment resulted in
reduced vascular hypertrophy, dilation, tortuosity, and
leakiness in multiple tumor models, therefore indicating a
possible link between TAM polarization and vessel
normalization. In addition, TAM polarization strongly
augments antitumor immune responses and improves the
antitumor efficacy of suboptimal doses of chemotherapeu-
tic drugs, i.e., doxorubicin [92]. This study provides the
first experimental evidence linking TAM polarization with
normalization of tumor vasculature, highlighting the con-
cept of reprograming TAMs as a novel strategy to improve
other cancer therapies, such as chemotherapy and
immunotherapy.
Conclusions
Although hypoxia and VEGF are well-recognized as
tumor-derived or intrinsic signals in promoting tumor
vascularization, the crucial roles of non-maliganant cells
within the TME in orchestrating this complex process
has only recently been appreciated. A growing body of
evidence indicates that TAMs, heterogeneous and func-
tionally distinct myeloid cells, are directly involved in
the tumor “angiogenic switch” and excessive tumor
vascularization. Mobilization of macrophages and their
polarization toward an alternatively activated or M2-like
phenotype not only contributes to tumor growth, pro-
gression and invasion, but also negatively influences
tumor responses to anti-angiogenic or anti-vascular
treatments, and cytotoxic therapies. Myeloid cells, espe-
cially TAMs, promote abnormal blood vessel formation
that subsequently limit chemotherapeutic efficacy [144].
Additionally, TAMs function as important participants in
tumor revascularization following RT and facilitate can-
cer relapse [139]. Therefore, targeting TAMs by blocking
their pro-angiogenic functions or reprogramming them
toward an angiostatic, tumoricidal and immunostimula-
tory phenotype represent a potentially novel strategy in
anti-angiogenic therapies and other conventional cancer
treatments (Figure 1). Considering TAM polarization in
the TME, “re-educating” and reprogramming TAMs to
convert them into antitumor effectors is now emerging
as a novel approach for “normalizing” tumor vasculature
and remodeling the immune microenvironment. See a re-
cent review by Squadrito and De Palma on pro-angio-
genic macrophage and cancer therapy [153] for more
details. These TAM-targeted strategies are being tested in
preclinical and clinical settings for their use in conjunc-
tion with conventional cancer treatment modalities,
such as chemotherapy, RT or immunotherapy, to
achieve improved therapeutic efficacy. In addition,
immune-based approaches to redirect the TAM pheno-
type for tumor rejection are clearly worth pursuing [154].
Nonetheless, much work remains in order to define and
elucidate the mechanistic basis of TAM polarization and
vessel normalization in the TME, which may lead to the
identification of novel targets for therapeutic intervention
of tumor vascularization or “re-education” of TAMs.
Continuing research to understand the interactions
between cancer cells and stromal cells, including TAMs
or other myeloid cells, in the TME are fundamental to
the rational design of future cancer treatments.
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